Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New substance selectively blocks Alzheimer’s enzyme

26.02.2016

For the first time, an international team headed by scientists from the University of Zurich has found a way to specifically inhibit an enzyme that is partly responsible for Alzheimer’s disease. The method involves blocking only harmful processes, while other important functions remain intact. This paves the way for new drugs to be developed that don’t cause any severe side effects.

For decades, intensive research has been conducted on drugs all over the world to treat Alzheimer’s patients. Although major progress has been made in diagnostics (the disease can be detected increasingly early and accurately), the therapeutic options remain limited.


UZH Researchers have shown that it is possible to inhibit the Alzheimer’s disease process specifically without affecting the physiological processes using induced pluripotent stem cell-derived neurons. (Image: UZH)

Together with researchers in Switzerland, Germany and India, the team headed by Professor Lawrence Rajendran from the Systems and Cell Biology of Neurodegeneration at the Institute of Regenerative Medicine of the University of Zurich has now developed a targeted substance that blocks the pathogenic function of an enzyme in the cells without affecting its other vital functions.

Protein deposits in the brain are hallmarks of Alzheimer’s disease and partly responsible for the chronically progressive necrosis of the brain cells. Nowadays, these plaques can be detected at very early stages, long before the first symptoms of dementia appear. The protein clumps mainly consist of the β amyloid peptide (Aβ), a protein fragment that forms when two enzymes, β and γ secretase, cleave the amyloid precursor protein (APP) into three parts, including Aβ, which is toxic.

Blocking the harmful process without affecting any useful functions

If β or γ secretase is blocked, this also inhibits the production of any more harmful β amyloid peptide. Consequently, for many years biomedical research has concentrated on these two enzymes as therapeutic points of attack. To date, however, the results of clinical studies using substances that block γ secretase have been sobering. The problem is that the enzyme is also involved in other key cell processes. Inhibiting the enzymes in patients therefore triggered severe side effects, such as gastrointestinal hemorrhaging or skin cancer.

Thus, for a number of years researchers have also been focusing their efforts on β secretase. A large number of substances have been developed, including some highly promising ones that reduced the amount of Aβ in mouse models effectively. Nevertheless, according to cell biologist Rajendran, this presents the same challenge: “The current β secretase inhibitors don’t just block the enzyme function that drives the course of Alzheimer’s, but also physiologically important cell processes. Therefore, the substances currently being tested in clinical studies may also trigger nasty side effects – and thus fail.”

Promising substance to be studied on Alzheimer’s patients

To address this, the first author on the publication, Saoussen Ben Halima in the lab of Professor Rajendran, and her fellow researchers studied how β secretase might be inhibited selectively – in other words, the harmful property blocked without affecting any useful functions. In a series of experiments, the scientists were able to demonstrate that the Alzheimer’s protein APP is cleft by β secretase in endosomes, special areas of the cells that are separated by membrane envelopes, while the other vital proteins are processed in other areas of the cell. The researchers exploited this spatial separation of the protein processing within the cell.

“We managed to develop a substance that only inhibits β secretase in the endosomes where the β amyloid peptide forms. The specific efficacy of our inhibitor opens up a promising way to treat Alzheimer’s effectively in future, without causing the patients any serious side effects,” says Rajendran in summary. The researchers’ next goal is to hone their drug candidate so that it can initially be tested in mice and ultimately in clinical studies on Alzheimer’s patients.

Literature:
Saoussen Ben Halima, Sabyashachi Mishra, K. Muruga Poopathi Raja, Michael Willem, Antonio Baici, Kai Simons, Oliver Brüstle, Philipp Koch, Christian Haass, Amedeo Caflisch, and Lawrence Rajendran. Specific Inhibition of β-Secretase Processing of the Alzheimer’s Disease Amyloid Precursor Protein. Cell Reports. February 25, 2016. doi: 10.1016/j.celrep.2016.01.076

Alzheimer’s and dementia in figures

Around eight percent of over-65s and more than 30 percent of people who are younger than 90 suffer from Alzheimer’s or another form of dementia. According to the Swiss Alzheimer’s Association, around 120,000 people living in this country currently suffer from dementia – a figure that is set to rise to 200,000 patients by 2030 on account of demographic developments. Dementia is already the most common reason for needing care in old age in Switzerland and the third most common cause of death after cardiovascular disease and cancer.

Contact:
Prof. Lawrence Rajendran
Institute of Regenerative Medicine
Psychiatric University Hospital
University of Zurich
Phone: +41 44 634 88 60
E-mail: rajendran@bli.uzh.ch

Weitere Informationen:

http://www.mediadesk.uzh.ch/articles/2016/neuer-wirkstoff-blockiert-alzheimer-enzym-gezielt_en.html

Kurt Bodenmüller | Universität Zürich
Further information:
http://www.uzh.ch/

More articles from Life Sciences:

nachricht Ruby: Jacobs University scientists are collaborating in the development of a new type of chocolate
18.09.2017 | Jacobs University Bremen gGmbH

nachricht German scientists question study about plastic-eating caterpillars
15.09.2017 | Johannes Gutenberg-Universität Mainz

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

Im Focus: Artificial Enzymes for Hydrogen Conversion

Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.

Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

IVAM’s LaserForum visits the Swiss canton of St. Gallen with the topic ultrashort pulse lasers

06.09.2017 | Event News

 
Latest News

Robust and functional – surface finishing by suspension spraying

19.09.2017 | Materials Sciences

The Wadden Sea and the Elbe Studied with Zeppelin, Drones and Research Ships

19.09.2017 | Earth Sciences

Digging sensors out of an efficiency hole

19.09.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>